{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,30]],"date-time":"2023-09-30T05:26:35Z","timestamp":1696051595957},"reference-count":38,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[1997,6,1]],"date-time":"1997-06-01T00:00:00Z","timestamp":865123200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Immunol Cell Biol"],"published-print":{"date-parts":[[1997,6]]},"abstract":"<jats:p>The antitumour efficacy of Ida\u2010anti\u2010Ly\u20102.1 immunoconjugate in combination with murine TNF\u2010\u03b1 (mTNF\u2010\u03b1) has been evaluated in a disseminated murine thymic lymphoma model E3. This tumour model shows characteristics similar to lymphoma in humans with widely disseminated tumour in major organs. <jats:italic>In vitro<\/jats:italic> both idarubicin (Ida) and Ida\u2010anti\u2010Ly\u20102.1 showed additive and synergistic cytotoxic effects, respectively, with mTNF\u2010\u03b1 when tested using the isobolagram method. Similar synergistic effects were also seen <jats:italic>in vivo.<\/jats:italic> Tumour\u2010bearing mice were treated with various doses of mTNF\u2010\u03b1 and Ida alone, however, neither showed a therapeutic response in mice. When mice were treated with Ida\u2010anti\u2010Ly\u20102.1 \u2018early\u2019 the median survival time (MST) was increased by 8 days, however, \u2018late\u2019 treatment was ineffective. Combination therapy of mTNF\u2010\u03b1 and Ida\u2010anti\u2010Ly\u20102.1 conjugate (42 \u03bcg) given \u2018early\u2019 was capable of curing 50% of mice. However, when tumour\u2010bearing mice were given a high dose (234 \u03bcg) of Ida\u2010anti\u2010Ly\u20102.1 together with mTNF\u2010\u03b1 100% of mice survived disease free. Such an effect was not observed when free mTNF\u2010\u03b1. Ida\u2010anti\u2010Ly\u20102.1. anti\u2010Ly\u20102.1 or a mixture of anti\u2010Ly\u20102.1 + mTNF\u2010\u03b1 was given at the same dose. These results show that a combination of very toxic drug immunoconjugates and TNF could lead to the eradication of disseminated tumour m mice and may be relevant for the treatment of minimal residual disease in cancer patients.<\/jats:p>","DOI":"10.1038\/icb.1997.39","type":"journal-article","created":{"date-parts":[[2007,5,21]],"date-time":"2007-05-21T18:50:24Z","timestamp":1179773424000},"page":"253-258","source":"Crossref","is-referenced-by-count":2,"title":["Tumour eradication with high\u2010dose idarubicin\u2010anti\u2010Ly\u20102.1 with murine tumour necrosis factor\u2010\u03b1 in mice"],"prefix":"10.1111","volume":"75","author":[{"given":"Geoffrey A","family":"Pietersz","sequence":"first","affiliation":[{"name":"The Austin Research Institute, Austin Hospital  Heidelberg Victoria Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary","family":"Bogdanovski","sequence":"additional","affiliation":[{"name":"The Austin Research Institute, Austin Hospital  Heidelberg Victoria Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Wenjun","sequence":"additional","affiliation":[{"name":"The Austin Research Institute, Austin Hospital  Heidelberg Victoria Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[1997,6]]},"reference":[{"key":"e_1_2_1_2_1","first-page":"25","article-title":"The use of anthracycline antibody complexes for specific anti\u2010tumor therapy","volume":"1","author":"Pietersz GA","year":"1988","journal-title":"Targeted Diagn. Ther."},{"key":"e_1_2_1_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01525435"},{"key":"e_1_2_1_4_1","first-page":"57","article-title":"Antibody conjugates for the treatment of cancer","volume":"129","author":"Pietersz GA","year":"1942","journal-title":"Immunol. Res."},{"key":"e_1_2_1_5_1","first-page":"62","article-title":"Selective enhancement of antitumor activity of N\u2010acetyl meiphalan on conjugation to monoclonal antibodies","volume":"47","author":"Smyth MJ","year":"1987","journal-title":"Cancer Res."},{"key":"e_1_2_1_6_1","first-page":"310","article-title":"The antitumour activity of idarubicin\u2010monoclonal antibody conjugates in a disseminated thymoma model","volume":"51","author":"Smyth MJ","year":"1991","journal-title":"Cancer Res."},{"key":"e_1_2_1_7_1","doi-asserted-by":"publisher","DOI":"10.1021\/bc00014a007"},{"key":"e_1_2_1_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/icb.1993.19"},{"key":"e_1_2_1_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1987.2"},{"key":"e_1_2_1_10_1","first-page":"127","article-title":"Immunoconjugates containing novel may tansinoids: Promising anticancer drugs","volume":"52","author":"Chari RVJ","year":"1992","journal-title":"Cancer Res."},{"key":"e_1_2_1_11_1","first-page":"1367","article-title":"Use of vasoactive agents to increase tumor perfusion and the antitumor efficacy of drug\u2010monoclonal antibody conjugates","volume":"79","author":"Smyth MJ","year":"1987","journal-title":"J. Natl Cancer Inst."},{"key":"e_1_2_1_12_1","doi-asserted-by":"publisher","DOI":"10.3109\/10611869408996804"},{"key":"e_1_2_1_13_1","first-page":"83","volume-title":"Recent advances in chemotherapy","author":"Aggarwal BB","year":"1985"},{"key":"e_1_2_1_14_1","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.4049\/jimmunol.135.3.2069","article-title":"Activation of human polymorphonuclear neutrophil functions by interferon\u2010\u03b3 and tumor necrosis factors","volume":"135","author":"Shalaby MR","year":"1985","journal-title":"J. Immunol."},{"key":"e_1_2_1_15_1","doi-asserted-by":"publisher","DOI":"10.1615\/CritRevImmunol.v16.i1.10"},{"key":"e_1_2_1_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/0277-5379(86)90107-0"},{"key":"e_1_2_1_17_1","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.4049\/jimmunol.133.3.1083","article-title":"The synergistic anti\u2010proliferative effect of r\u2010interferon and human lymphotoxin","volume":"133","author":"Lee SH","year":"1984","journal-title":"J. Immunol."},{"key":"e_1_2_1_18_1","first-page":"304","article-title":"Potentiation of in vitro antitumor effect of lymphotoxin by antitumor drugs and elevated temperature","volume":"26","author":"Khan A","year":"1985","journal-title":"Proc. Am. Assoc. Cancer Res."},{"key":"e_1_2_1_19_1","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.4049\/jimmunol.112.6.2111","article-title":"Cell\u2010mediated immunity in vitro: a highly sensitive assay for human lymphotoxin","volume":"112","author":"Spofford BT","year":"1974","journal-title":"J. Immunol."},{"key":"e_1_2_1_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1992.10.1.52"},{"key":"e_1_2_1_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910390224"},{"key":"e_1_2_1_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/9780470513521.ch8"},{"key":"e_1_2_1_23_1","first-page":"1408","article-title":"Combination cytokine immunotherapy with tumour necrosis factor \u03b1, interleukin 2, and \u03b1\u2010interferon, and its synergistic antitumor effects in mice","volume":"49","author":"McIntosh JK","year":"1989","journal-title":"Cancer Res."},{"key":"e_1_2_1_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910400222"},{"key":"e_1_2_1_25_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.80.17.5397"},{"key":"e_1_2_1_26_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.84.12.4273"},{"key":"e_1_2_1_27_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.72.9.3666"},{"key":"e_1_2_1_28_1","first-page":"659","article-title":"Endotoxin. interleukin\u20101 and tumor necrosis factor cause neutrophil\u2010dependent microvascular leakage in postcapillary venules","volume":"140","author":"Ii ES","year":"1992","journal-title":"Am. J. Pathol."},{"key":"e_1_2_1_29_1","first-page":"3607","article-title":"Increased antitumour effect of immunoconjugates and tumor necrosis factor in vivo","volume":"48","author":"Smyth MJ","year":"1988","journal-title":"Cancer Res."},{"key":"e_1_2_1_30_1","first-page":"6028","article-title":"Effect of tumor necrosis factor on the antitumor efficacy and toxicity of aminopterin\u2010monoclonal antibody conjugates: parameters in optimization of therapy","volume":"50","author":"Russell S","year":"1990","journal-title":"Cancer Res."},{"key":"e_1_2_1_31_1","first-page":"135","article-title":"Monoclonal antibodies to murine Ly\u20102.1 cell surface antigen","volume":"46","author":"Hogarth PM","year":"1982","journal-title":"Immunology"},{"key":"e_1_2_1_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/0161-5890(78)90070-6"},{"key":"e_1_2_1_33_1","first-page":"926","article-title":"Immunochemotherapy of a murine thymoma with idarubicin\u2010monoclonal antibody conjugates","volume":"48","author":"Pietersz GA","year":"1988","journal-title":"Cancer Res."},{"key":"e_1_2_1_34_1","first-page":"503","article-title":"The specific targeting of chlorambucil to tumours","volume":"76","author":"Smyth MJ","year":"1986","journal-title":"J. Natl Cancer Inst."},{"key":"e_1_2_1_35_1","first-page":"1","article-title":"Synergy, additivism and antagonism in immunosuppression","volume":"28","author":"Berenbaum MC","year":"1977","journal-title":"Clin. Exp Immunol."},{"key":"e_1_2_1_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/0014-5793(91)80803-B"},{"key":"e_1_2_1_37_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1990.78"},{"key":"e_1_2_1_38_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198702123160705"},{"key":"e_1_2_1_39_1","doi-asserted-by":"publisher","DOI":"10.1002\/eji.1830170517"}],"container-title":["Immunology &amp; Cell Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1038%2Ficb.1997.39","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/icb199739","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/icb199739.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1038\/icb.1997.39","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/www.nature.com\/articles\/icb199739.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T06:41:16Z","timestamp":1695969676000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1038\/icb.1997.39"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1997,6]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[1997,6]]}},"alternative-id":["10.1038\/icb.1997.39"],"URL":"https:\/\/doi.org\/10.1038\/icb.1997.39","archive":["Portico"],"relation":{},"ISSN":["0818-9641","1440-1711"],"issn-type":[{"value":"0818-9641","type":"print"},{"value":"1440-1711","type":"electronic"}],"subject":[],"published":{"date-parts":[[1997,6]]}}}